Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing.
Telomerase is a ribonucleoprotein complex responsible for the maintenance of the length of the telomeres during cell division, which is active in germ-line cells as well as in the vast majority of tumors but not in most normal tissues. The wide expression of the human telomerase catalytic subunit (hTERT) in tumors makes it an interesting candidate vaccine for cancer. hTERT-derived peptide 540-548 (hTERT(540)) has been recently shown to be recognized in an HLA-A*0201-restricted fashion by T cell lines derived from peptide-stimulated peripheral blood mononuclear cells (PBMC) from healthy donors. As a first step to the inclusion of this peptide in immunotherapy clinical trials, it is crucial to assess hTERT(540)-specific T cell reactivity in cancer patients as well as the ability of hTERT-specific CD8(+) T lymphocytes to recognize and lyse hTERT-expressing target cells. Here, we have analyzed the CD8(+) T cell response to peptide hTERT(540) in HLA-A*0201 melanoma patients by using fluorescent HLA-A*0201/hTERT(540) peptide tetramers. HLA-A*0201/hTERT(540) tetramer(+) CD8(+) T cells were readily detected in peptide-stimulated PBMC from a significant proportion of patients and could be isolated by tetramer-guided cell sorting. hTERT(540)-specific CD8(+) T cells were able to specifically recognize HLA-A*0201 cells either pulsed with peptide or transiently transfected with a minigene encoding the minimal epitope. In contrast, they failed to recognize hTERT-expressing HLA-A*0201(+) target cells. Furthermore, in vitro proteasome digestion studies revealed inadequate hTERT processing. Altogether, these results raise questions on the use of hTERT(540) peptide for cancer immunotherapy.
Ayyoub
M
M
Division of Clinical Onco-immunology, Ludwig Institute for Cancer Research, University Hospital, Lausanne, Switzerland. Maha.Ayyoub@chuv.hospvd.ch
Migliaccio
M
M
Guillaume
P
P
Liénard
D
D
Cerottini
J C
JC
Romero
P
P
Lévy
F
F
Speiser
D E
DE
Valmori
D
D
D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000276:immunology*; D002460:Cell Line; D002999:Clone Cells; D003546:Cysteine Endopeptidases / Q000494:pharmacology; D003601:Cytotoxicity Tests, Immunologic; D000939:Epitopes / Q000276:immunology; D005434:Flow Cytometry; D015234:HLA-A Antigens / Q000276:immunology; D006801:Humans; D008545:Melanoma / Q000276:immunology*; D009097:Multienzyme Complexes / Q000494:pharmacology; D010446:Peptide Fragments / Q000235:genetics / Q000276:immunology*; D046988:Proteasome Endopeptidase Complex; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D019098:Telomerase / Q000235:genetics / Q000276:immunology*; D014162:Transfection; D014407:Tumor Cells, Cultured
D000951:Antigens, Neoplasm; D000939:Epitopes; D015234:HLA-A Antigens; D009097:Multienzyme Complexes; D010446:Peptide Fragments; C437311:telomerase reverse transcriptase (540-548); D019098:Telomerase; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex